Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

IMAAVY™ (nipocalimab-aahu)

Medical Information

IMAAVY - Comparison to Other Neonatal Fragment Crystallizable Receptor Blockers in Patients with Generalized Myasthenia Gravis

Last Updated: 04/30/2025

SUMMARY

There are no head-to-head, randomized, controlled clinical trials comparing the safety and efficacy of IMAAVY to other neonatal fragment crystallizable receptor (FcRn) blockers in patients with generalized myasthenia gravis (gMG).

Literature Search

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) conducted on 11 November 2024 did not identify any relevant citations.

Endchat

Chat live